title: Antiretroviral therapy management and rationalisation of available resources.
abstract: The treatment of HIV disease has led to a new division of management costs by shifting most of the necessary resources from inpatient treatment to outpatient management. Among the initiatives aimed at rationalising the resources available, we compared efficacy, tolerability and pharmacoeconomic impact of different regimes of antiretroviral therapy (ART). The survey covered the first 50 patients, clinically stable and with good viro-immunological response, who switched in June 2012 from an ART based on the triple combination of tenofovir (TDF), emtricitabine (FTC) and a protease inhibitor boosted with ritonavir (PI/r) or a non-nucleoside reverse transcriptase inhibitor (NNRTI), to a treatment based on abacavir (ABC), lamivudine (3TC) and a PI/r or NNRTI. Of the 50 patients who operated the switch, 39 replaced a PI with nevirapine (NVP), for which the largest group of patients was treated with ABC + 3TC + NVP. On 31 May 2015, all patients completed the observation period of 96 weeks, with a mean observation period of 132 weeks and clinical-laboratory checks every four months. Laboratory analysis revealed an optimal maintenance of viral suppression and absolute and relative number of CD4 + lymphocytes and improving trend of creatinine, proteinuria, serum phosphate and bone alkaline phosphatase. There was a variable effect on lipids, with a drop in triglycerides associated with a modest increase in total cholesterol. Much of the HIV-positive population reporting to our hospitals (>50%) comprises individuals who have for years been in stable viraemic suppression, making a satisfactory immune recovery while in good overall clinical condition. This type of patient was the target of the present survey. At the end of 96 weeks of observation the new regimes were well tolerated and did not lead to viro-immunological or clinical deterioration. Pharmacoeconomic analysis showed better containment of the overall costs. No patient needed to be hospitalised during the observation period.
authors.affiliation: Malattie Infettive, Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Oscar
authors.initials: O
authors.lastname: Cirioni
authors.affiliation: Malattie Infettive, Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Sefora
authors.initials: S
authors.lastname: Castelletti
authors.affiliation: Clinica di Malattie Infettive, Dipartimento Medico, Università Gabriele D'Annunzio di Chieti-Pescara, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Ucciferri
authors.affiliation: Clinica di Malattie Infettive, Dipartimento Medico, Università Gabriele D'Annunzio di Chieti-Pescara, Italy.
authors.forename: Katia
authors.initials: K
authors.lastname: Falasca
authors.affiliation: Malattie Infettive, Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Orsetti
authors.affiliation: Malattie Infettive, Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Susanna
authors.initials: S
authors.lastname: Mazzocato
authors.affiliation: Malattie Infettive, Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Valeriani
authors.affiliation: Dipartimento di Malattie Infettive, Università La Sapienza, Rome, Italy.
authors.forename: Francesco Maria
authors.initials: FM
authors.lastname: Di Campli
authors.affiliation: Malattie Infettive, Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Barchiesi
authors.affiliation: Clinica di Malattie Infettive, Dipartimento Medico, Università Gabriele D'Annunzio di Chieti-Pescara, Italy.
authors.forename: Jacopo
authors.initials: J
authors.lastname: Vecchiet
authors.affiliation: Malattie Infettive, Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Giacometti
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000191:economics / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000191:economics / Q000379:methods*; D015224:Dideoxynucleosides / Q000191:economics / Q000627:therapeutic use*; D000068679:Emtricitabine / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D019438:Ritonavir / Q000191:economics / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D000068698:Tenofovir / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D000068679:Emtricitabine; D019438:Ritonavir; D000068698:Tenofovir; D000099227:Abacavir